Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Fintel reports that on April 17, 2025, BMO Capital downgraded their outlook for Novo Nordisk A (NYSE:NVO) from Outperform to ...

We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

So far this year, Pfizer shares have dropped 17.4%, while Novo Nordisk's stock has tumbled 24% and Lilly shares have slipped 3.2%. The SPDR S&P Pharmaceuticals ETF XPH has shed 12.1% year to date and ...

That's good news for Recursion Pharmaceuticals ( RXRX 3.67%), a biotech company that's already pioneering the use of AI in drug development. Recursion's shares soared on the news, but the stock ...

President Donald Trump has ordered the Department of Health and Human Services to standardize Medicare payments in an effort ...

The headquarters is located in Copenhagen (Denmark) with offices in San Francisco, Boston and Singapore. The total assets of Novo Holdings amount to 108 billion euros. Novo Nordisk is a corporate fund ...

Denmark's Novo Nordisk has agreed to pay $70 million to license rights to a drug developed by Ventus Therapeutics with potential in non-alcoholic steatohepatitis (NASH) and several other diseases ...